SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark receives final approval from USFDA for Desonide Ointment

19 Sep 2017 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Desonide Ointment, 0.05%, the generic version of Desonide Ointment, 0.05%, of Perrigo New York Inc.

According to IMS Health sales data for the 12 month period ending July 2017, the Desonide Ointment, 0.05% market achieved annual sales of approximately $23.4 million.

Glenmark’s current portfolio consists of 124 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

2307.70 -29.50 (-1.26%)
24-Apr-2026 09:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1638.00
Dr. Reddys Lab 1318.20
Cipla 1285.60
Zydus Lifesciences 930.95
Lupin 2316.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×